Key pathways that could be relevant to C20orf173's function include the PI3K/Akt/mTOR pathway, the MAPK/ERK pathway, and the ubiquitin-proteasome system. Rapamycin and LY294002, by inhibiting mTOR and PI3K respectively, can affect cell growth and survival pathways. U0126 and PD98059, targeting MEK in the MAPK/ERK pathway, are involved in cell differentiation and proliferation, potentially intersecting with C20orf173-related processes.
Inhibitors like Bortezomib and MG132 target the proteasome, affecting protein turnover and degradation, which can influence a range of cellular signaling pathways. DAPT, as a γ-secretase inhibitor, affects Notch signaling, a pathway significant in cell fate decisions and differentiation.These inhibitors represent a broad spectrum of cellular targets and processes, offering potential indirect means to influence the activity of C20orf173
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), affecting calcium homeostasis. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor, which can indirectly affect apoptosis pathways, potentially influencing C20orf173-related processes. | ||||||